General issues related to medical research and federal banking guidance.
Continued issues surrounding the implementation of the CARES Act.
General issues related to medical research.
General issues related to the legal status of cannabis.
Issues relating to Section 280E of the Internal Revenue Code.
Duration: January 1, 2018
to
January 31, 2021
General Issues: Banking , Medical/Disease Research/Clinical Labs , Agriculture , Taxation/Internal Revenue Code , Budget/Appropriations
Spending: about $740,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Treasury - Dept of, Small Business Administration (SBA), Executive Office of the President (EOP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Christopher Cox
Special Asst. for Leg Affairs to President George W. Bush
Special Assistant for Legislative Affairs for President George W Bush
Susan Nelson
n/a
Phil Anderson
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2021
Navigators Global LLC (Formerly DC Navigators, LLC) terminated an engagement in which they represented Curaleaf, Inc. (formerly known as PalliaTech Inc.) on April 20, 2021.
Original Filing: 301266325.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
Continued issues surrounding the implementation of the CARES Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of Small Business Administration (SBA)
Lobbying Issues
General issues related to medical research.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General issues related to the legal status of cannabis.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Section 280E of the Internal Revenue Code.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. (formerly known as PalliaTech Inc.) , earning $60,000. The report was filed on Jan. 21, 2021.
Original Filing: 301245483.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 & S.1200 - SAFE Banking Act of 2019.
Implementation of the CARES Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of Small Business Administration (SBA)
Lobbying Issues
General issues related to medical research.
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Section 280E of the Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. (formerly known as PalliaTech Inc.) , earning $60,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222775.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 & S.1200 - SAFE Banking Act of 2019.
Implementation of the CARES Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of Small Business Administration (SBA)
Lobbying Issues
General issues related to medical research.
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Section 280E of the Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. (formerly known as PalliaTech Inc.) , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301202243.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 & S.1200 - SAFE Banking Act of 2019
H.R. 748 & S. 3548 - CARES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of Small Business Administration (SBA)
Lobbying Issues
General issues related to medical research.
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Section 280E of the Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. (formerly known as PalliaTech Inc.) , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301179315.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 & S.1200 - SAFE Banking Act of 2019
H.R. 748 & S. 3548 - CARES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of Small Business Administration (SBA)
Lobbying Issues
General issues related to medical research.
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 & H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to Section 280E of the Internal Revenue Code
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2019
In Q4, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. (formerly known as PalliaTech Inc.) , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127994.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 & S.1200 - SAFE Banking Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to medical research.
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. (formerly known as PalliaTech Inc.) , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301076650.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 & S.1200 - SAFE Banking Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to medical research.
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
2nd Quarter, 2019
In Q2, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. (formerly known as PalliaTech Inc.) , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301058346.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 & S.1200 - SAFE Banking Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to medical research.
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
1st Quarter, 2019
Navigators Global LLC (Formerly DC Navigators, LLC) amended a lobbying report for representation of Curaleaf, Inc. (formerly known as PalliaTech Inc.) in Q12019 on April 23, 2019.
Original Filing: 301038986.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 - SAFE Banking Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to medical research.
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
1st Quarter, 2019
In Q1, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for Curaleaf, Inc. , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301037402.xml
Lobbying Issues
General issues related to medical research and federal banking guidance.
H.R.1595 - SAFE Banking Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to medical research.
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1028 - STATES Act
H.R.2093 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
4th Quarter, 2018
In Q4, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for PalliaTech Inc. , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015366.xml
Lobbying Issues
Lobbying on medical research issues
Issues related to federal banking guidance
S.3032 - STATES Act
H.R.6043 - STATES Act
H.R.5634 - Medical Cannabis Research Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbying on medical research issues
H.R.5952 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019
S.3072 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbying on medical research issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
In Q3, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for PalliaTech Inc. , earning $60,000. The report was filed on Oct. 19, 2018.
Original Filing: 300992289.xml
Lobbying Issues
Lobbying on medical research issues
Issues related to federal banking guidance
S.3032 - STATES Act
H.R.6043 - STATES Act
H.R.5634 - Medical Cannabis Research Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbying on medical research issues
H.R.5952 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019
S.3072 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbying on medical research issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for PalliaTech Inc. , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300976752.xml
Lobbying Issues
Lobbying on medical research issues
Issues related to federal banking guidance
S.3032 - STATES Act
H.R.6043 - STATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbying on medical research issues
H.R.5952 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019
S.3072 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbying on medical research issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
Navigators Global LLC (Formerly DC Navigators, LLC) filed a lobbying registration on April 20, 2018 to represent PalliaTech Inc., effective Jan. 1, 2018.
Original Filing: 300954888.xml
Issue(s) they said they’d lobby about: Lobbying on medical research issues.
H.R.1625, Consolidated Appropriations Act .
1st Quarter, 2018
In Q1, Navigators Global LLC (Formerly DC Navigators, LLC) lobbied for PalliaTech Inc. , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300956905.xml
Lobbying Issues
Lobbying on medical research issues
Issues related to federal banking guidance
Agencies Lobbied
U.S. Senate U.S. House of Representatives Treasury - Dept of
Lobbying Issues
Lobbying on medical research issues
H.R.1625, Consolidated Appropriations Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbying on medical research issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate